Deals In Depth: October 2016
Executive Summary
To satisfy conditions of its St. Jude acquisition, Abbott divested certain cardiovascular devices to Terumo for over $1 billion; Astellas strengthened its oncology pipeline by acquiring Ganymed for $1.4 billion. ConvaTec's $1.8 billion IPO on the LSE propelled device financings past $2billion.